These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 21546833)

  • 1. Neurocognitive impairment and neuroCART.
    Wright E
    Curr Opin HIV AIDS; 2011 Jul; 6(4):303-8. PubMed ID: 21546833
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Does use of antiretroviral therapy regimens with high central nervous system penetration improve survival in HIV-infected adults?
    McManus H; Li PC; Nolan D; Bloch M; Kiertiburanakul S; Choi JY; Mulhall B; Petoumenos K; Zhou J; Law M; Brew BJ; Wright E
    HIV Med; 2011 Nov; 12(10):610-9. PubMed ID: 21819527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neurocognitive dysfunction in the highly active antiretroviral therapy era.
    Mothobi NZ; Brew BJ
    Curr Opin Infect Dis; 2012 Feb; 25(1):4-9. PubMed ID: 22156897
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neurological disease: the effects of HIV and antiretroviral therapy and the implications for early antiretroviral therapy initiation.
    Wright EJ
    Curr Opin HIV AIDS; 2009 Sep; 4(5):447-52. PubMed ID: 20048710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Unmet therapeutic needs in the new era of combination antiretroviral therapy for HIV-1.
    Taiwo B; Hicks C; Eron J
    J Antimicrob Chemother; 2010 Jun; 65(6):1100-7. PubMed ID: 20348088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improvements in antiretroviral therapy outcomes over calendar time.
    Boyd MA
    Curr Opin HIV AIDS; 2009 May; 4(3):194-9. PubMed ID: 19532050
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protease inhibitor monotherapy and the CNS: peace of mind?
    Perez-Valero I; Bayon C; Cambron I; Gonzalez A; Arribas JR
    J Antimicrob Chemother; 2011 Sep; 66(9):1954-62. PubMed ID: 21672918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Can high central nervous system penetrating antiretroviral regimens protect against the onset of HIV-associated neurocognitive disorders?
    Vassallo M; Durant J; Biscay V; Lebrun-Frenay C; Dunais B; Laffon M; Harvey-Langton A; Cottalorda J; Ticchioni M; Carsenti H; Pradier C; Dellamonica P
    AIDS; 2014 Feb; 28(4):493-501. PubMed ID: 24472743
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Benefit or toxicity from neurologically targeted antiretroviral therapy?
    Brew BJ
    Clin Infect Dis; 2010 Mar; 50(6):930-2. PubMed ID: 20146628
    [No Abstract]   [Full Text] [Related]  

  • 10. [National consensus document by GESIDA/National Aids Plan on antiretroviral treatment in adults infected by the human immunodeficiency virus (January 2011 update)].
    Panel de expertos de GESIDA y Plan Nacional sobre el Sida
    Enferm Infecc Microbiol Clin; 2011 Mar; 29(3):209.e1-103. PubMed ID: 21388714
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV-associated neurocognitive disorders (HAND).
    Elbirt D; Mahlab-Guri K; Bezalel-Rosenberg S; Gill H; Attali M; Asher I
    Isr Med Assoc J; 2015 Jan; 17(1):54-9. PubMed ID: 25739180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neurocognitive functioning in pediatric human immunodeficiency virus infection: effects of combined therapy.
    Shanbhag MC; Rutstein RM; Zaoutis T; Zhao H; Chao D; Radcliffe J
    Arch Pediatr Adolesc Med; 2005 Jul; 159(7):651-6. PubMed ID: 15996999
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early antiretroviral therapy: the role of cohorts.
    Sabin CA
    Curr Opin HIV AIDS; 2009 May; 4(3):200-5. PubMed ID: 19532051
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 15. When and why to start antiretroviral therapy?
    Gatell JM
    J Antimicrob Chemother; 2010 Mar; 65(3):383-5. PubMed ID: 20071369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patients.
    Ciccarelli N; Fabbiani M; Di Giambenedetto S; Fanti I; Baldonero E; Bracciale L; Tamburrini E; Cauda R; De Luca A; Silveri MC
    Neurology; 2011 Apr; 76(16):1403-9. PubMed ID: 21502598
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interrogating the impact of combination antiretroviral therapies on HIV-associated neurocognitive disorders.
    Sharma I
    HIV Med; 2021 Oct; 22(9):783-790. PubMed ID: 34291558
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neurocognitive screening tools in HIV/AIDS: comparative performance among patients exposed to antiretroviral therapy.
    Skinner S; Adewale AJ; DeBlock L; Gill MJ; Power C
    HIV Med; 2009 Apr; 10(4):246-52. PubMed ID: 19187172
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reaping the prevention benefits of highly active antiretroviral treatment: policy implications of HIV Prevention Trials Network 052.
    Forsyth AD; Valdiserri RO
    Curr Opin HIV AIDS; 2012 Mar; 7(2):111-6. PubMed ID: 22227586
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV-related neurocognitive impairment--a review.
    Rackstraw S
    Psychol Health Med; 2011 Oct; 16(5):548-63. PubMed ID: 21745034
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.